CTD STRUCTURE

Dr Monica Hemben Eimunjeze

Director Registration & Regulatory Affairs

Please note that this presentation should not be copied or distributed without the explicit approval of NAFDAC
 • The Common Technical Document is one of the
outputs of the ICH which are known as ICH Topics

• The topics are divided into four categories known

Introduction as Quality, Safety, Efficacy, Multidisciplinary (Q, S,
E, M)

• The CTD is found under the multidisciplinary

topic

CTD Training - NAFDAC Requirements for Dossier Submission 19 - 21 February 2020 2

 • The CTD for has several advantages

• Harmonised submissions

• Enabled implementation of good review practices

Introduction • Eliminated the need to reformat the information for

submission to the different regulatory authorities

• Complete and well-organized submissions

• More predictable format

• More consistent reviews

  Easier analysis across applications

 Easier exchange of information

 Faster review times for applications

Introduction
 Facilitates electronic submission

 Accelerate access to affordable and quality-

assured medicines and health commodities

CTD Training - NAFDAC Requirements for Dossier Submission 19 - 21 February 2020 4

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 5
 Module 1

Module 2

Module 3

Module 4

Module 5

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 6

 1.0 Cover Letter

1.1 Table of Contents

(Module 1 – 5)

1.2
Application Information

Second Level
1.3 Product Information Folder
(Child)
1.4 Regional Summaries

Module 1 Electronic Review Documents

1.5

1.6 Samples
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 7
 1.0

Cover Letter Document should

be searchable

1.1

Table of Contents Module 1 – 5

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 8
 1.2.1

1.2 1.2.2 Third Level

Folder

……. (Grandchild)

1.2.18

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 9

 1.2.1

Application Letter
In searchable pdf

1.2.2

……. Registration Form

1.2.18
Additional Strength Biowaiver
19 - 21 February 2020
Request Form
CTD Training - NAFDAC Requirements for Dossier Submission 10
Sub – Folders Under Application Information
(1.2)

• 18 Sub-Folders under 1.2:

• 1.2.1 – Application Letter
• 1.2.2 – Registration Form
• 1.2.3 – Certificate of Incorporation
• 1.2.4 – Power of Attorney
• 1.2.5 – Notarised Declaration of the Applicant
• 1.2.6 – Contract Manufacturing Agreement
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 11
 • 1.2.7 – Certificate of Pharmaceutical Product (COPP)
• 1.2.8 – Certificate of Good Manufacturing Practice
• 1.2.9 – Manufacturing Authorisation
• 1.2.10 – Evidence of Trade Mark Registration
• 1.2.11 – Superintendent Pharmacist’s Annual Licence
to Practice
• 1.2.12 – Certificate of Registration and Retention of
Premises
• 1.2.13 – Evidence of Previous Marketing Authorisation
• 1.2.14 – Invitation Letter for GMP Inspection

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 12

 • 1.2.15 – Copy of Certificate of Suitability (CEP) where
applicable
• 1.2.16 – Letter of Access for APIMF(s) where applicable
• 1.2.17 – Biowaiver Request in relation to conducting
BCS-based bioavailability study
• 1.2.18 – Biowaiver request in relation to conducting
Additional Strength bioavailability study

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 13

Sub – Folders Under Product Information (1.3)
• 3 Sub-Folders under 1.3:
• 1.3.1 – Summary of Product Characteristics (SmPC)
• 1.3.2 – Labelling (Inner and outer)
• 1.3.3 – Package Insert (also known as Patient Information
Leaflet PIL)

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 14

Sub – Folders Under Regional Summaries (1.4)

• 2 Sub-Folders under 1.4:

• 1.4.1 – Bioequivalence Trial Information Form (BTIF)
• 1.4.2 – Quality Information Summary (QIS

Note: There are no sub-folder for 1.5 and 1.6

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 15

 2.1 CTD Table of Contents (Mod. 2 – 5 )

2.2 CTD Introduction

2.3 Quality Overall Summary

2.4 Non-Clinical Overview

2.5 Clinical Overview

Module 2
2.6 Non-Clinical Summary

2.7 Clinical Summary

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 16
 3.1 Table of Contents (Module 3)

3.2 Body of Data

Module 3

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 17

 3.2.A Appendices

3.2.P Drug Product

3.2
3.2.R Regional Information
Body of Data

3.2.S Drug Substance

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 18
 3.2.S.1 General Information

3.2.S.2 Manufacture

3.2.S.3 Characterisation

3.2.S.4 Control of Drug Substance

3.2.S

3.2.S.5 Reference Standards and Materials

Drug Substance
3.2.S.6 Container Closure System

3.2.S.7 Stability
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 19
Sub-Folders under Drug Substance (S.1 – S.7)

• 3 Sub-Folders under 3.2.S.1:

• 3.2.S.1.1 – Nomenclature
• 3.2.S.1.2 – Structure
• 3.2.S.1.3 – General Properties

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 20

 • 6 Sub-Folders under 3.2.S.2:
• 3.2.S.2.1 – Manufacturer(s)
• 3.2.S.2.2 – Description of Manufacturing Process and Controls
• 3.2.S.2.3 – Control of Materials
• 3.2.S.2.4 – Control of Critical Steps and Intermediates
• 3.2.S.2.5 – Process Validation and/or Evaluation
• 3.2.S.2.6 – Manufacturing Process Development

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 21

• 2 Sub-Folders under 3.2.S.3:
• 3.2.S.3.1 – Elucidation of Structure and Other
Characteristics
• 3.2.S.3.2 – Impurities

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 22

 • 5 Sub-Folders under 3.2.S.4:
• 3.2.S.4.1 – Specification
• 3.2.S.4.2 – Analytical Procedures
• 3.2.S.4.3 – Validation of Analytical Procedures
• 3.2.S.4.4 – Batch Analyses
• 3.2.S.4.5 – Justification of Specification

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 23

 • 3 Sub-Folders under 3.2.S.7:
• 3.2.S.7.1 – Stability Summary and Conclusion
• 3.2.S.7.2 – Post Approval Stability Protocol and Stability
Commitment
• 3.2.S.7.3 – Stability Data

Note: There are no sub-folders under 3.2.S.5 and 3.2.S.6

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 24

 3.2.P.1 Description and Composition

3.2.P.2 Pharmaceutical Development

3.2.P.3 Manufacture

3.2.P.4 Control of Excipients

3.2.P 3.2.P.5 Control of Drug Product

Drug Product 3.2.P.6 Reference Standards and Materials

3.2.P.7 Container Closure System

3.2.P.8 Stability

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 25

 Sub-Folders under Drug Product (P.1 – P.8)

• 5 Sub-Folders under 3.2.P.3:

• 3.2.P.3.1 – Manufacturer(s)
• 3.2.P.3.2 – Batch Formula
• 3.2.P.3.3 – Description of Manufacturing Process and
Process Controls
• 3.2.P.3.4 – Control of Critical Steps and Intermediates
• 3.2.P.3.5 – Process Validation and/or Evaluation

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 26

 • 6 Sub-Folders under 3.2.P.4:
• 3.2.P.4.1 – Specifications
• 3.2.P.4.2 – Analytical Procedures
• 3.2.P.4.3 – Validation of Analytical Procedures
• 3.2.P.4.4 – Justification of Specifications
• 3.2.P.4.5 – Excipients of Human or Animal Origin
• 3.2.P.4.6 – Novel Excipients

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 27

 • 6 Sub-Folders under 3.2.P.5:
• 3.2.P.5.1 – Specification(s)
• 3.2.P.5.2 – Analytical Procedures
• 3.2.P.5.3 – Validation of Analytical Procedures
• 3.2.P.5.4 – Batch Analyses
• 3.2.P.5.5 – Characterisation of Impurities
• 3.2.P.5.6 – Justification of Specification(s)

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 28

 • 3 Sub-Folders under 3.2.P.8:
• 3.2.P.8.1 – Stability Summary and Conclusion
• 3.2.P.8.2 – Post Approval Stability Protocol &
Commitment
• 3.2.P.8.3 – Stability Data

• Note: There are no sub-folders under 3.2.P.1, 3.2.P.2, 3.2.P.6

& 3.2.P.7

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 29

 Sub – Folders under Appendices (3.2.A)

• 3 Sub-Folders under 3.2.A:

• 3.2.A.1 – Facilities and Equipment
• 3.2.A.2 – Adventitious Agents Safety Evaluation
• 3.2.A.3 – Novel Excipients

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 30

 Sub – Folders Under Regional Information
(3.2.R)
• 2 Sub-Folders under 3.2.R:
• 3.2.R.1 – Production Documentation
• 3.2.R.2 – Analytical Procedures and Validation
Information

• 3.2.R.1 is separated further into:

• 3.2.R.1.1 – Executed Production Documents
• 3.2.R.1.2 – Master Production Documents

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 31

Module 4 – Nonclinical Study Reports
• This section is not applicable to generic products
• Will usually not be provided in the dossier submission

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 32

 5.1 CTD Table of Contents for Module 5

5.2 Tabular Listing of All Clinical Studies

Module 5 5.3 Clinical Study Reports

5.4 Literature References

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 33
 5.3.1 Biopharmaceutics Study Reports

5.3.2 Pharmacokinetic Studies

Using Human Biomaterials

5.3.3 Human Pharmacokinetic (PK)

Studies

Human Pharmacodynamic (PD)

5.3.4
5.3 Studies

5.3.5
Safety and Efficacy Study
Reports

Reports of Post-Marketing
5.3.6
Expereince

5.3.7 Case Study Report Forms and

Individual Patient Listings
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 34
Sub – Folders under Biopharmaceutics Study
Reports (5.3.1)
• 4 Sub-Folders under 5.3.1:

• 5.3.1.1 – Bioavailability (BA) Reports

• 5.3.1.2 – Comparative BA and Bioequivalence (BE) Study Reports
• 5.3.1.3 – In Vitro – In Vivo Correlation Study Reports
• 5.3.1.4 – Reports of Bioanalytical and Analytical Methods for
Human Studies

Note: There are no sub-folders under section 5.3.7.

19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 35
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 36
19 - 21 February 2020 CTD Training - NAFDAC Requirements for Dossier Submission 37